JP5356819B2 - 真菌類の分類および抗菌治療のための試薬、方法およびキット - Google Patents
真菌類の分類および抗菌治療のための試薬、方法およびキット Download PDFInfo
- Publication number
- JP5356819B2 JP5356819B2 JP2008532349A JP2008532349A JP5356819B2 JP 5356819 B2 JP5356819 B2 JP 5356819B2 JP 2008532349 A JP2008532349 A JP 2008532349A JP 2008532349 A JP2008532349 A JP 2008532349A JP 5356819 B2 JP5356819 B2 JP 5356819B2
- Authority
- JP
- Japan
- Prior art keywords
- probe
- hybridization
- pna
- sensitive
- probe set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 17
- 230000002538 fungal effect Effects 0.000 title description 8
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 239000000523 sample Substances 0.000 claims abstract description 205
- 241000233866 Fungi Species 0.000 claims abstract description 47
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 56
- 229960004884 fluconazole Drugs 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 39
- 238000009396 hybridization Methods 0.000 claims description 39
- 150000007523 nucleic acids Chemical group 0.000 claims description 33
- 229940121375 antifungal agent Drugs 0.000 claims description 28
- 238000004458 analytical method Methods 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 230000000843 anti-fungal effect Effects 0.000 claims description 19
- 108010020326 Caspofungin Proteins 0.000 claims description 18
- 229960003034 caspofungin Drugs 0.000 claims description 17
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 16
- 238000007901 in situ hybridization Methods 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 11
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 8
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 7
- 241001496375 Iris albicans Species 0.000 claims description 7
- 229960003942 amphotericin b Drugs 0.000 claims description 7
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 7
- 229960004740 voriconazole Drugs 0.000 claims description 7
- 241000222122 Candida albicans Species 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 15
- 230000000845 anti-microbial effect Effects 0.000 abstract description 2
- 241000894007 species Species 0.000 description 38
- 230000035945 sensitivity Effects 0.000 description 24
- 230000001419 dependent effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 239000003429 antifungal agent Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 208000037815 bloodstream infection Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 6
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000222178 Candida tropicalis Species 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002853 nucleic acid probe Substances 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 241000222173 Candida parapsilosis Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 4
- 206010017523 Fungaemia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000197813 Camelina sativa Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000222126 [Candida] glabrata Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 208000032343 candida glabrata infection Diseases 0.000 description 2
- 229940055022 candida parapsilosis Drugs 0.000 description 2
- -1 candins Chemical compound 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001508813 Clavispora lusitaniae Species 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical compound OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 241000278923 Tropicoporus tropicalis Species 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940062768 amphotericin b liposomal Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960000730 caspofungin acetate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IWBOPFCKHIJFMS-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl) ether Chemical compound NCCOCCOCCN IWBOPFCKHIJFMS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical compound CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71915305P | 2005-09-20 | 2005-09-20 | |
| US60/719,153 | 2005-09-20 | ||
| US78965606P | 2006-04-05 | 2006-04-05 | |
| US60/789,656 | 2006-04-05 | ||
| PCT/US2006/036645 WO2007035814A2 (en) | 2005-09-20 | 2006-09-20 | Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009508531A JP2009508531A (ja) | 2009-03-05 |
| JP2009508531A5 JP2009508531A5 (enExample) | 2009-10-22 |
| JP5356819B2 true JP5356819B2 (ja) | 2013-12-04 |
Family
ID=37889500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532349A Expired - Fee Related JP5356819B2 (ja) | 2005-09-20 | 2006-09-20 | 真菌類の分類および抗菌治療のための試薬、方法およびキット |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20070082351A1 (enExample) |
| EP (1) | EP1945810B1 (enExample) |
| JP (1) | JP5356819B2 (enExample) |
| AU (1) | AU2006292174B2 (enExample) |
| CA (1) | CA2623181A1 (enExample) |
| WO (1) | WO2007035814A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2735735C (en) | 2008-09-02 | 2016-11-22 | The Governing Council Of The University Of Toronto | Nanostructured microelectrodes and biosensing devices incorporating the same |
| ES2704685T3 (es) | 2011-01-11 | 2019-03-19 | Governing Council Univ Toronto | Método para la detección de proteínas |
| EP3369828B1 (en) * | 2011-02-07 | 2020-07-15 | The Governing Council Of The University Of Toronto | Bioprobes and methods of use thereof |
| JP5990987B2 (ja) * | 2012-04-11 | 2016-09-14 | 株式会社Ihi | 微生物固定方法、および微生物検出方法 |
| EP3071965A1 (en) | 2013-11-21 | 2016-09-28 | Avails Medical, Inc. | Electrical biosensor for detecting a substance in a bodily fluid, and method and system for same |
| US9963733B2 (en) | 2014-06-05 | 2018-05-08 | Avails Medical, Inc. | Devices, systems and methods for detecting viable infectious agents in a fluid sample |
| EP4368991A3 (en) * | 2015-08-25 | 2024-08-14 | Avails Medical, Inc. | Devices, systems and methods for detecting viable microorganisms in a fluid sample |
| FR3044415B1 (fr) * | 2015-11-27 | 2017-12-01 | Biomerieux Sa | Procede de determination de la reaction d'un microorganisme a son exposition a un antibiotique |
| EP3356511B1 (en) | 2016-01-25 | 2022-04-27 | Avails Medical, Inc. | Methods for detecting viable infectious agents in a fluid sample using an electrolyte-insulator-semiconductor sensor |
| EP3464551B1 (en) | 2016-05-31 | 2024-07-03 | Avails Medical, Inc. | Detecting viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives |
| WO2018111234A1 (en) | 2016-12-13 | 2018-06-21 | Avails Medical, Inc. | DEVICES, SYSTEMS AND METHODS TO DETECT THE PRESENCE OF ß-LACTAM ANTIBIOTIC HYDROLYZING BACTERIA IN A SAMPLE |
| WO2019005296A1 (en) | 2017-06-27 | 2019-01-03 | Avails Medical, Inc. | APPARATUS, SYSTEMS AND METHODS FOR DETERMINING THE SENSITIVITY OF MICROORGANISMS TO ANTI-INFECTIOUS |
| JP7209701B2 (ja) | 2017-10-03 | 2023-01-20 | アベイルズ メディカル，インコーポレイテッド | レドックス反応に基づいて微生物の濃度及び抗感染剤に対する微生物の感受性を決定する装置、システム、及び方法 |
| CN117451472A (zh) | 2017-12-05 | 2024-01-26 | 阿威尔斯医疗公司 | 制备用于下游测试的包含确定浓度的感染原的输出样品 |
| AU2019337088A1 (en) | 2018-09-03 | 2021-05-06 | Visby Medical, Inc. | Devices and methods for antibiotic susceptibility testing |
| CA3115289A1 (en) | 2018-10-04 | 2020-04-09 | First Light Diagnostics, Inc. | Test cartridges |
| WO2020117650A1 (en) | 2018-12-03 | 2020-06-11 | Avails Medical, Inc. | Apparatus, systems, and methods for quantifying infectious agents |
| US11352675B2 (en) * | 2020-01-03 | 2022-06-07 | Visby Medical, Inc. | Devices and methods for antibiotic susceptability testing |
| CN112458145B (zh) * | 2021-01-06 | 2021-06-04 | 健康元海滨药业有限公司 | 一种注射用醋酸卡泊芬净制剂的无菌检测方法 |
| CN117551801A (zh) * | 2023-09-25 | 2024-02-13 | 中国医学科学院北京协和医院 | 分子标记及其应用和基于erg11基因拷贝数检测近平滑念珠菌氟康唑耐药性的方法和系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| CA2025180A1 (en) | 1989-10-12 | 1991-04-13 | William G. Weisburg | Nucleic acid probes and methods for detecting pathogenic candida yeasts |
| US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5763169A (en) * | 1995-01-13 | 1998-06-09 | Chiron Diagnostics Corporation | Nucleic acid probes for the detection and identification of fungi |
| US6235890B1 (en) * | 1996-09-16 | 2001-05-22 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for the detection of Candida spp. |
| US20020098483A1 (en) | 1996-10-22 | 2002-07-25 | Jurgen Loffler | Method for detecting resistant fungal cells in clinical material |
| DE19654946A1 (de) * | 1996-10-22 | 1998-05-07 | Univ Eberhard Karls | Verfahren zum Nachweis von resistenten Pilzzellen in klinischem Material |
| US6242178B1 (en) * | 1997-07-30 | 2001-06-05 | Centers For Disease Control And Prevention | Nucleic acid probes for detecting Candida species |
| JP4963765B2 (ja) * | 1999-05-28 | 2012-06-27 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 |
| CA2399364A1 (fr) * | 2000-02-08 | 2001-08-16 | Aventis Pharma S.A. | Procede de detection et de quantification d'adenovirus |
| WO2001083821A2 (en) * | 2000-05-01 | 2001-11-08 | Gen-Probe Incorporated | Polynucleotide probes for detection and quantitation of candida species |
| DE10053821A1 (de) * | 2000-10-30 | 2002-05-08 | Univ Eberhard Karls | Detektion von seltenen Candida-Spezies |
| JP2002142775A (ja) * | 2000-11-14 | 2002-05-21 | Ss Pharmaceut Co Ltd | カンジダ属真菌検出用核酸及びそれを用いたカンジダ属真菌の検出方法 |
| EP1417333B1 (en) * | 2001-05-18 | 2011-10-05 | Boston Probes, Inc. | Pna probes, probe sets, methods and kits pertaining to the detection of candida |
| US20050054516A1 (en) | 2003-09-05 | 2005-03-10 | Vaughn Stephen Neil | Processes for formulating catalyst compositions having desirable particle size characteristics |
| JP4790621B2 (ja) * | 2003-11-26 | 2011-10-12 | アドバンディーエックス， インコーポレイテッド | 特定のＳｔａｐｈｙｌｏｃｏｃｃｕｓ種の分析のためのペプチド核酸プローブ |
-
2006
- 2006-09-20 EP EP06815025.9A patent/EP1945810B1/en not_active Not-in-force
- 2006-09-20 AU AU2006292174A patent/AU2006292174B2/en not_active Ceased
- 2006-09-20 US US11/524,988 patent/US20070082351A1/en not_active Abandoned
- 2006-09-20 CA CA002623181A patent/CA2623181A1/en not_active Abandoned
- 2006-09-20 JP JP2008532349A patent/JP5356819B2/ja not_active Expired - Fee Related
- 2006-09-20 WO PCT/US2006/036645 patent/WO2007035814A2/en not_active Ceased
-
2008
- 2008-10-15 US US12/288,051 patent/US8795972B2/en not_active Expired - Fee Related
-
2014
- 2014-06-26 US US14/315,696 patent/US20140342356A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009508531A (ja) | 2009-03-05 |
| AU2006292174A1 (en) | 2007-03-29 |
| EP1945810A2 (en) | 2008-07-23 |
| EP1945810B1 (en) | 2015-07-01 |
| EP1945810A4 (en) | 2009-07-22 |
| WO2007035814A2 (en) | 2007-03-29 |
| US20070082351A1 (en) | 2007-04-12 |
| WO2007035814A8 (en) | 2015-10-08 |
| AU2006292174B2 (en) | 2012-02-23 |
| US8795972B2 (en) | 2014-08-05 |
| US20090092994A1 (en) | 2009-04-09 |
| US20140342356A1 (en) | 2014-11-20 |
| CA2623181A1 (en) | 2007-03-29 |
| WO2007035814A3 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5356819B2 (ja) | 真菌類の分類および抗菌治療のための試薬、方法およびキット | |
| US6753421B2 (en) | Probes for the detection of mycobacteria | |
| JP3608823B2 (ja) | 真菌の検出および真菌の菌種同定用オリゴヌクレオチド | |
| US8377656B2 (en) | Compositions and methods for detecting Cryptococcus neoformans | |
| JP4886784B2 (ja) | カンジダ種の検出のための組成物および方法 | |
| JP7334964B2 (ja) | Ｉｌｖ３を使用した微生物の検出及び設計 | |
| EP1709198B1 (en) | Peptide nucleic acid probes for analysis of certain staphylococcus species | |
| US9663827B2 (en) | Molecular gram stain | |
| AU2006252346B2 (en) | Peptide nucleic acid probes for analysis of microorganisms | |
| EP2152906B1 (en) | Peptide nucleic acid probes for analysis of certain staphylococcus species | |
| JP5621992B2 (ja) | カンジダ種を検出および同定するための方法 | |
| KR20100042464A (ko) | 시료 중의 살모넬라 풀로룸 및 살모넬라 갈리나룸 중 하나 이상의 존재를 검출하는 방법 및 키트 | |
| JP2004201636A (ja) | 病原真菌遺伝子の検出方法及び真菌の菌種同定用オリゴヌクレオチド | |
| JP2004201637A (ja) | 病原真菌遺伝子の検出及びそれに用いるオリゴヌクレオチド | |
| CN114867868A (zh) | 用于检测结核分枝杆菌、鸟分枝杆菌及胞内分枝杆菌的引物组、及使用了该引物组的方法、以及用于该方法的试剂盒 | |
| CN101448954A (zh) | 用于真菌分类的试剂、方法和试剂盒以及抗真菌疗法的指导 | |
| JP2017225413A (ja) | オリゴヌクレオチド、アスペルギルス・テレウス検出用プローブ、及びアスペルギルス・テレウス検出方法 | |
| HK1149592B (en) | Peptide nucleic acid probes for analysis of microorganisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090902 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120321 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120618 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130108 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130116 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130207 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130806 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130829 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |